JAMES M. FRATES - 03 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Director
Signature: Brandon Marsh, as Attorney-in-Fact for James M Frates
Issuer symbol: SAGE
Transactions as of: 03 Jan 2025
Transactions value $: $0
Form type: 4
Filing time: 06 Jan 2025, 16:02:45 UTC
Previous filing: 16 Sep 2024
Next filing: 10 Mar 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Options (Right to buy)	Award	$0	+19,154		$0.000000	19,154	03 Jan 2025	Common Stock	19,154	$6.14	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2025 on the issuer's board or its committees, as permitted under the issuer's non-employee director compensation program. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The option will vest in full on December 31, 2025, subject to the reporting person's continued service through such date.

Content

The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2025 on the issuer's board or its committees, as permitted under the issuer's non-employee director compensation program. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The option will vest in full on December 31, 2025, subject to the reporting person's continued service through such date.